Our results suggest that monocytes or the circulating levels of S100A9 or S10012 could be analyzed to give prognostic information for prostate cancer patients diagnosed with metastases, and possibly also to identify patients in need of complementary treatment to the conventional androgen-deprivation therapy. The gene discussed is S100A9; the disease is prostate carcinoma.